Latest News
ScreenPoint Medical reveals FDA approval for Breast AI Transpara's new capabilities
3 December 2024 - ScreenPoint Medical, a Dutch developer of AI for breast cancer detection and diagnosis, on Monday announced US Food and Drug Administration (FDA) approval for innovative new capabilities of its Breast AI Transpara.Breast AI Transpar...
Spyre Therapeutics commences dosing in Phase 1 trials of half-life extended anti-TL1A antibodies
3 December 2024 - Clinical-stage biotechnology company Spyre Therapeutics Inc (NASDAQ: SYRE) announced on Monday that it has commenced dosing of healthy volunteers in Phase 1 clinical trials of two investigational half-life extended anti-TL1A monoclo...
MapLight Therapeutics announces ML-007/PAC Phase 1 trial results
3 December 2024 - Clinical-stage biopharmaceutical company MapLight Therapeutics on Monday announced results from its Phase 1 trial assessing the safety, tolerability and pharmacokinetics of ML-007/PAC in healthy adult and elderly volunteers.ML-007 h...
Rigel Pharmaceuticals' R289 granted US FDA Fast Track designation
3 December 2024 - Commercial stage biotechnology company Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced on Monday that it has received Fast Track designation from the US Food and Drug Administration (FDA) for R289 for the treatment of patients ...
Ampersand Capital acquires Nektar Therapeutics' PEGylation reagent manufacturing business
3 December 2024 - Ampersand Capital Partners, a private equity company specialising in growth equity investments in the life sciences and healthcare sectors, announced on Monday that it has completed its acquisition of US-based Nektar Therapeutics�...